Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update

Dow Jones10-29

By Josh Beckerman

Shuttle Pharmaceuticals Holdings shares surged after an update related to its Phase 2 clinical trial of ropidoxuridine, a radiation sensitizer for use in combination with radiation therapy to treat brain tumors.

The stock rose 63%, to $2.17, in after-hours trading Monday. As of the market close, shares were down about 63% for the year.

The company said it finalized agreements with all six planned site enrollment locations. Agreements were finalized with Georgetown University Medical Center and UNC Medical Center. It previously reported agreements with four other locations.

Shuttle said in early September that the Phase 2 trial had started enrolling patients with aggressive, IDH wild-type, methylation negative glioblastomas, the company said.

Earlier Monday, Shuttle said Chief Executive Anatoly Dritschilo would present at a ThinkEquity conference Wednesday morning. He will discuss the ropidoxuridine study and provide an update on plans for the Shuttle Diagnostics subsidiary to develop predictive biomarkers for prostate-cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 28, 2024 18:50 ET (22:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479380464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 06:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479380464","market":"hk","top_or_hot":-1,"title":"Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shuttle Pharmaceuticals Holdings shares surged after an update related to its Phase 2 clinical trial of ropidoxuridine, a radiation sensitizer for use in combination with radiation therapy to treat brain tumors. \n</p>\n<p>\n  The stock rose 63%, to $2.17, in after-hours trading Monday. As of the market close, shares were down about 63% for the year. \n</p>\n<p>\n  The company said it finalized agreements with all six planned site enrollment locations. Agreements were finalized with Georgetown University Medical Center and UNC Medical Center. It previously reported agreements with four other locations. \n</p>\n<p>\n  Shuttle said in early September that the Phase 2 trial had started enrolling patients with aggressive, IDH wild-type, methylation negative glioblastomas, the company said. \n</p>\n<p>\n  Earlier Monday, Shuttle said Chief Executive Anatoly Dritschilo would present at a ThinkEquity conference Wednesday morning. He will discuss the ropidoxuridine study and provide an update on plans for the Shuttle Diagnostics subsidiary to develop predictive biomarkers for prostate-cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 18:50 ET (22:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 06:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n \n\n\n  Shuttle Pharmaceuticals Holdings shares surged after an update related to its Phase 2 clinical trial of ropidoxuridine, a radiation sensitizer for use in combination with ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SHPH","symbol_name":"Shuttle Pharmaceuticals Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479380464","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479380464","pubTimestamp":1730155800,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shuttle Pharmaceuticals Holdings shares surged after an update related to its Phase 2 clinical trial of ropidoxuridine, a radiation sensitizer for use in combination with radiation therapy to treat brain tumors.The stock rose 63%, to $2.17, in after-hours trading Monday. As of the market close, shares were down about 63% for the year.The company said it finalized agreements with all six planned site enrollment locations. Agreements were finalized with Georgetown University Medical Center and UNC Medical Center. It previously reported agreements with four other locations.Shuttle said in early September that the Phase 2 trial had started enrolling patients with aggressive, IDH wild-type, methylation negative glioblastomas, the company said.Earlier Monday, Shuttle said Chief Executive Anatoly Dritschilo would present at a ThinkEquity conference Wednesday morning. He will discuss the ropidoxuridine study and provide an update on plans for the Shuttle Diagnostics subsidiary to develop predi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SHPH":"Shuttle Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"Shuttle Pharmaceuticals股价因药物研究网站更新而上涨63%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SHPH":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shuttle Pharmaceuticals Holdings shares surged after an update related to its Phase 2 clinical trial of ropidoxuridine, a radiation sensitizer for use in combination with radiation therapy to treat brain tumors. \n\n\n  The stock rose 63%, to $2.17, in after-hours trading Monday. As of the market close, shares were down about 63% for the year. \n\n\n  The company said it finalized agreements with all six planned site enrollment locations. Agreements were finalized with Georgetown University Medical Center and UNC Medical Center. It previously reported agreements with four other locations. \n\n\n  Shuttle said in early September that the Phase 2 trial had started enrolling patients with aggressive, IDH wild-type, methylation negative glioblastomas, the company said. \n\n\n  Earlier Monday, Shuttle said Chief Executive Anatoly Dritschilo would present at a ThinkEquity conference Wednesday morning. He will discuss the ropidoxuridine study and provide an update on plans for the Shuttle Diagnostics subsidiary to develop predictive biomarkers for prostate-cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 18:50 ET (22:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479380464"}